Shots:
- Alvotech reported EMA’s acceptance of its marketing application for AVT06, a biosimilar to Eylea used to treat eye disorders, and reported global sales of $5.9B. The company expects its marketing approval in Q3’25
- Alvotech will develop and supply the AVT06, while Advanz Pharma will register and have exclusive commercialization rights in Europe except for France and Germany, where Biogaran holds semi-exclusive rights
- On Jan’24, Alvotech reported the positive top-line data from its trial (AVT06-GL-C01) comparing the efficacy, safety, and immunogenicity of AVT06 with Eylea in patients with neovascular (wet) AMD, Furthermore, the company is also developing a high dose biosimilar of Eylea i.e. AVT29 (8mg)
Ref: Alvotech | Image: Alvotech | Press Release
Related News:- GlycoNex Reports the Completion of P-I Study Assessing SPD8 (Biosimilar, Prolia) for Osteoporosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
